Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
Human Vaccines & Immunotherapeutics · 2024
DOI: 10.1080/21645515.2024.2425147 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Human Vaccines & Immunotherapeutics, 2024. Verfasst von Vivek Shinde und 45 weiteren Autor:innen. Beteiligte Einrichtung: Research and Development, Novavax, Inc, Gaithersburg, MD, USA. Hauptthemen laut MEDLINE: COVID-19 Vaccines, HIV Infections, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novavax.
Abstract (Originalsprache)
COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study's pre-crossover/booster phase were previously reported. This phase 2a/b clinical trial in South Africa (2019nCoV-501/NCT04533399) revisits 1:1 randomly assigned HIV-negative adults (18-84 years) and medically stable PLWH (18-64 years) who previously received two NVX-CoV2373 doses (5 μg recombinant Spike protein with 50 μg Matrix-M™ adjuvant) or placebo. During the 6-month blinded crossover/booster phase, NVX-CoV2373 recipients could receive a single NVX-CoV2373 booster dose and placebo recipients a 2-dose NVX-CoV2373 primary series. NVX-CoV2373 safety and immunogenicity were assessed according to prior SARS-CoV-2 infection and HIV status. Post-crossover, 1900/3793 NVX-CoV2373 recipients were assigned another dose, and 1893/3793 placebo recipients were assigned NVX-CoV2373 primary series. Approximately 56% of the participants were SARS-CoV-2-seropositive ("seropositive") at crossover (6% PLWH). In seropositive participants (HIV-negative and PLWH), booster-dose anti-spike IgG, MN50 and hACE2 inhibition responses increased to similar levels, exceeding those in seronegative participants. In primary-series and booster cohorts, seronegative PLWH showed higher neutralizing responses (4.9- to 5.5-fold, respectively) versus peak pre-crossover primary-series responses. The safety profile was similar among the pre-crossover/booster phase groups; solicited and unsolicited adverse events were infrequent in all groups. A single NVX-CoV2373 booster dose substantially increased antibodies. All baseline seropositive participants showed higher immune responses than seronegative participants. These findings support use of NVX-CoV2373, including in immunocompromised individuals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research and Development, Novavax, Inc, Gaithersburg, MD, USA.
- South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- Research and Development, Josha Research Centre, Bloemfontein, Free State, South Africa.
- Paediatric Infectious Diseases Unit, University of KwaZulu-Natal, Durban, South Africa.
- Research and Development, Soweto Clinical Trials Centre, Johannesburg, South Africa.
- Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Förderung
- Novavax
Zitieren
APA
Shinde, V., Lombard Koen, A., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., Fouche, L. F., Louw, C., Tameris, M., Singh, N., Goga, A., Dheda, K., Grobbelaar, C., Joseph, N., Lombaard, J. J., …, & 2019nCoV-501 Study Group (2024). Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2024.2425147
Vancouver
Shinde V, Lombard Koen A, Hoosain Z, Archary M, Bhorat Q, Fairlie L, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Human Vaccines & Immunotherapeutics. 2024. doi:10.1080/21645515.2024.2425147
BibTeX
@article{Shinde2024,
author = {Shinde, Vivek and Lombard Koen, Anthonet and Hoosain, Zaheer and Archary, Moherndran and Bhorat, Qasim and Fairlie, Lee and Lalloo, Umesh and Masilela, Mduduzi S L and Moodley, Dhayendre and Hanley, Sherika and Fouche, Leon Frederik and Louw, Cheryl and Tameris, Michele and Singh, Nishanta and Goga, Ameena and Dheda, Keertan and Grobbelaar, Coert and Joseph, Natasha and Lombaard, Johan J and Mngqibisa, Rosie and Bhorat, As'ad Ebrahim and Benadé, Gabriella and Lalloo, Natasha and Pitsi, Anna and Vollgraaff, Pieter-Louis and Luabeya, Angelique and Esmail, Aliasgar and Petrick, Friedrich G and Oommen Jose, Aylin and Foulkes, Sharne and Ahmed, Khatija and Thombrayil, Asha and Kalonji, Dishiki and Cloney-Clark, Shane and Zhu, Mingzhu and Bennett, Chijioke and Albert, Gary and Marcheschi, Alex and Plested, Joyce S and Neal, Susan and Chau, Gordon and Cho, Iksung and Fries, Louis and Glenn, Greg M and Madhi, Shabir A and 2019nCoV-501 Study Group, 2019nCoV-501 Study Group},
title = {Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M TM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial},
journal = {Human Vaccines & Immunotherapeutics},
year = {2024},
doi = {10.1080/21645515.2024.2425147}
}
EUVIMED